The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat Topic 22-Feb-2018: Lung cancer research–Why we need it and how we can get more
- #LCSM Chat Topic 2/8/18: Right to Try Laws and CIMAVax
- #LCSM Chat 01/25: Open Mic Nite–What’s on your mind?
- #LCSM Chat Topic 1/11: Defining “hope” for lung cancer
- #LCSM Chat Topic 12/14: #LCSM Community 2017 Highlights, Visions for 2018
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day